strong>Eisai Co. Ltd., of Tokyo, reported that the French National Authority for Health's Transparency Commission has awarded Zonegran (zonisamide), its treatment of partial seizures, a Medical Benefit level of "important" and an Improvement of Medical Benefit level "V."